A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

Inclusion Criteria: * Has a parent/legally acceptable representative who is able to give documented informed consent * Has acute bacterial skin and skin structure infections (ABSSSI), defined as ≥1 of the following: 1) cellulitis/erysipelas, 2) major cutaneous abscess, or 3) wound infection * Local symptoms of ABSSSI that started within 14 days before study start * Suspected or documented Gram-positive bacterial infection Exclusion Criteria: * Uncomplicated skin and skin structure infection * ABSSSI due to or associated with disallowed etiology per protocol * Received antibacterial therapy for treatment of the current episode of ABSSSI except 1) \<48 hours of antibacterial therapy with a short-acting antibacterial drug, or 2) response is considered to be failure (no improvement in signs and symptoms) after at least 48 hours of therapy * Known bacteremia, severe sepsis, or septic shock * Significant or life-threatening condition, disease, or organ system condition * Recent history of opportunistic infections where the underlying cause of the infection is still active, or is suspected to be at risk of opportunistic infection with unusual pathogens * Received or is receiving treatment for active tuberculosis within 1 month of study start * Known or suspected severe neutropenia * Human immunodeficiency virus (HIV) positive and has Cluster of Differentiation (CD) 4 cell count \<15% (HIV testing is not required for eligibility) * Renal impairment that requires renal filtration * Severe hepatic impairment * Cardiac or electrocardiogram (ECG) finding that would limit participation in the study * Received an investigational medicinal product (not approved) within 30 days before study start * Investigational device present or removed within 30 days before study start * Previously treated with tedizolid phosphate * Contraindication, including hypersensitivity to tedizolid phosphate, other oxazolidinones, or any component in the formulation * Contraindication, including hypersensitivity to all available comparator drugs * Wound infection and history of hypersensitivity to aztreonam adjunctive therapy or metronidazole adjunctive therapy, if adjunctive therapy is required * Needs oral administration of methotrexate, topotecan, irinotecan, or rosuvastatin, during administration of oral study drug (administration during the follow-up period, ie, after the end of treatment (EOT) visit, is allowed, as is administration during treatment with IV drug) * Female who is pregnant or nursing or is of childbearing potential and not abstinent; or male who is not abstinent * Use of monoamine oxidase inhibitors, tricyclic antidepressants, buspirone, selective serotonin reuptake inhibitors, or serotonin 5-hydroxytryptamine receptor agonists (triptans) * Identified as having used illicit drugs (urine drug screening not required for entry)